Image source: Shutterstock

Highlights

  • Ord Minnett issues a BUY rating for IDX with a price target of AUD 3.00, indicating potential upside from current levels.

  • IDX has reported statutory loss of $0.4 million in latest half driven by one-off merger and restructuring expenses.

  • Operating NPAT rose 31.9% to $9.8 million in 1HFY25 and revenue grew 7.8% to $249.4 million (excluding Capitol contribution).

  • Fully franked interim dividend of 2.5 cents per share to be paid on 7 April 2025.

 

Integral Diagnostics Ltd (ASX:IDX) currently holds a “Buy” rating from analysts at Ord Minnett, with a target price of AUD 3.00, representing an upside potential of approximately 22.95% from its current price. Overall, the consensus recommendation mean stands at 1.64, translating to a "Buy" rating, and the average target price is AUD 3.14, up 28.69%. 

Company Overview

Integral Diagnostics (IDX) is a premier provider of medical imaging services across Australia and New Zealand. The company operates under a unique medical leadership model, employing some of the region's most experienced radiologists and diagnostic imaging professionals. This structure ensures high standards of patient care, access, and service—underscoring its core belief that “Good medicine is good business.”

Latest Financial Performance

For the half-year ended 31 December 2024, IDX reported a statutory loss after tax of AUD 0.4 million, primarily due to AUD 9.2 million in transaction and integration-related expenses and a AUD 1.3 million loss from the Capitol acquisition during its short period under IDX control. Excluding Capitol, the company posted strong operating results: revenue rose by 7.8% to AUD 249.4 million, operating EBITDA was AUD 46.8 million (an 8.2% increase), and operating NPAT grew 31.9% to AUD 9.8 million. Free cash flow was robust at AUD 29.4 million, up 22.7%. On a pro forma basis, operating diluted EPS was 3.6 cents (up 14.2%), and net debt to EBITDA was 2.6x, below the target threshold of 3.0x. A fully franked interim dividend of 2.5 cents per share is set to be paid on 7 April 2025.